Sunanda Mallik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sunanda Mallik has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Christian Schlieker
Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06511, USA
2 shared publications - Vanessa Todorow
Yale University, New Haven, CT, USA
2 shared publications - Brigitte S. Naughton
Department of Chemistry and Biochemistry, University of California , Santa Barbara, California 93106, United States
1 shared publication - Chandrayee Mukherjee
Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06511, USA
1 shared publication - Dylan Poch
Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 06511
1 shared publication - E. F. Elsiena Kuiper
Biomedical Sciences, University of Groningen, University Medical Center Groningen, 9713 AV, Groningen, the Netherlands
1 shared publication
Latest Publications
- Open Access
- 15 July 2025
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 224 (9)
Nodal modulator (NOMO) is a force-bearing transmembrane protein required for muscle differentiation
The ER relies on membrane-shaping proteins to maintain a continuous network of sheets and tubules that host distinct biological processes. How this intricate structure of the ER membrane system is maintained under conditions of mechanical strain is incompletely understood. NOMO is an ER-resident transmembrane protein that contributes to ER morphology and is highly expressed in striated muscle. In this study, we identify a critical interface between distal Ig domains that enables NOMO to maintain ER morphology and bear mechanical forces. By incorporating two independent tension sensors in the luminal domain of NOMO, we demonstrate that NOMO assemblies experience forces in the single piconewton range, with a significant contribution from the identified interface. These newly defined features are important—if not indispensable—for myogenesis, as interface mutations affecting mechanosensitivity fail to restore the essential role of NOMO during myogenesis in a C2C12 differentiation model. Moreover, NOMO depletion impairs nematode motility, underscoring a broader functional importance in muscle physiology.
- 15 July 2025
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 224 (9)
Open AccessNodal modulator (NOMO) is a force-bearing transmembrane protein required for muscle differentiation
The ER relies on membrane-shaping proteins to maintain a continuous network of sheets and tubules that host distinct biological processes. How this intricate structure of the ER membrane system is maintained under conditions of mechanical strain is incompletely understood. NOMO is an ER-resident transmembrane protein that contributes to ER morphology and is highly expressed in striated muscle. In this study, we identify a critical interface between distal Ig domains that enables NOMO to maintain ER morphology and bear mechanical forces. By incorporating two independent tension sensors in the luminal domain of NOMO, we demonstrate that NOMO assemblies experience forces in the single piconewton range, with a significant contribution from the identified interface. These newly defined features are important—if not indispensable—for myogenesis, as interface mutations affecting mechanosensitivity fail to restore the essential role of NOMO during myogenesis in a C2C12 differentiation model. Moreover, NOMO depletion impairs nematode motility, underscoring a broader functional importance in muscle physiology.
- Open Access
Integrative Chemical Genetics Platform Identifies Condensate Modulators Linked to Neurological Disorders
Aberrant biomolecular condensates are implicated in multiple incurable neurological disorders, including Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and DYT1 dystonia. However, the role of condensates in driving disease etiology remains poorly understood. Here, we identify myeloid leukemia factor 2 (MLF2) as a disease-agnostic biomarker for phase transitions, including stress granules and nuclear condensates associated with dystonia. Exploiting fluorophore-derivatized MLF2 constructs, we developed a high-content platform and computational pipeline to screen modulators of NE condensates across chemical and genetic space. We identified RNF26 and ZNF335 as protective factors that prevent the buildup of nuclear condensates sequestering K48-linked polyubiquitinated proteins. Chemical screening identified four FDA-approved drugs that potently modulate condensates by resolving polyubiquitinated cargo and MLF2 accumulation. Our exploratory integrated chemical-genetics approach suggests that modulation of zinc, and potentially autophagy and oxidative stress, is critical for condensate modulation and nuclear proteostasis, offering potential therapeutic strategies for neurological disorders. Application of our platform to a genome-wide CRISPR KO screen identified strong enrichment of candidate genes linked to primary microcephaly and related neurodevelopmental disorders. Two hypomorphic microcephaly-associated alleles of ZNF335 failed to rescue nuclear condensate accumulation in ZNF335 KO cells, suggesting that aberrant condensates and impaired nuclear proteostasis may contribute to the pathogenesis of microcephaly. HIGHLIGHTS MLF2 emerges as a disease-agnostic condensate biomarker co-localizing with TDP-43 and G3BP1 FDA-approved drugs target condensates linked to perturbed proteostasis. RNF26 and ZNF335 are identified as modulators of nuclear phase transitions. Microcephaly patient disease alleles fail to counteract aberrant condensates.
Open AccessIntegrative Chemical Genetics Platform Identifies Condensate Modulators Linked to Neurological Disorders
Aberrant biomolecular condensates are implicated in multiple incurable neurological disorders, including Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and DYT1 dystonia. However, the role of condensates in driving disease etiology remains poorly understood. Here, we identify myeloid leukemia factor 2 (MLF2) as a disease-agnostic biomarker for phase transitions, including stress granules and nuclear condensates associated with dystonia. Exploiting fluorophore-derivatized MLF2 constructs, we developed a high-content platform and computational pipeline to screen modulators of NE condensates across chemical and genetic space. We identified RNF26 and ZNF335 as protective factors that prevent the buildup of nuclear condensates sequestering K48-linked polyubiquitinated proteins. Chemical screening identified four FDA-approved drugs that potently modulate condensates by resolving polyubiquitinated cargo and MLF2 accumulation. Our exploratory integrated chemical-genetics approach suggests that modulation of zinc, and potentially autophagy and oxidative stress, is critical for condensate modulation and nuclear proteostasis, offering potential therapeutic strategies for neurological disorders. Application of our platform to a genome-wide CRISPR KO screen identified strong enrichment of candidate genes linked to primary microcephaly and related neurodevelopmental disorders. Two hypomorphic microcephaly-associated alleles of ZNF335 failed to rescue nuclear condensate accumulation in ZNF335 KO cells, suggesting that aberrant condensates and impaired nuclear proteostasis may contribute to the pathogenesis of microcephaly. HIGHLIGHTS MLF2 emerges as a disease-agnostic condensate biomarker co-localizing with TDP-43 and G3BP1 FDA-approved drugs target condensates linked to perturbed proteostasis. RNF26 and ZNF335 are identified as modulators of nuclear phase transitions. Microcephaly patient disease alleles fail to counteract aberrant condensates.